Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets
Mol Biol Rep. 2021 Oct 20. doi: 10.1007/s11033-021-06752-9. Online ahead of print.ABSTRACTCancer immunotherapy is a rapidly evolving concept that has been given the tag "fifth pillar" of cancer therapy while radiation therapy, chemotherapy, surgery and targeted therapy remain the other four pillars. This involves the stimulation of the immune system to control tumor growth and it specifically targets the neoplastic cells rather than the normal cells. Conventional chemotherapy has many limitations which include drug resistance, recurrence of cancer and severe adverse effects. Immunology has made major treatment breakthroughs for several cancers such as colorectal cancer, prostate cancer, breast cancer, lung cancer, liver cancer, kidney cancer, stomach cancer, acute lymphoblastic leukaemia etc. Currently, therapeutic strategies harnessing the immune system involve Checkpoint inhibitors, Chimeric antigen receptor T cells (CAR T cells), Monoclonal antibodies, Cancer vaccines, Cytokines, Radio-immunotherapy and Oncolytic virus therapy. The molecular characterization of several tumor antigens (TA) indicates that these TA can be utilized as promising candidates in cancer immunotherapy strategies. Here in this review, we highlight and summarize the different categories of emerging cancer immunotherapies along with the immunologically recognized tumor antigens involved in the tumor microenvironment.PMID:34671902 | DOI:10.1007/s11033-021-06752-9
Hospital refusing heart transplant for man who won't get vaccinated Brigham and Women's Hospital in Boston says its policy won't allow DJ Ferguson to have the surgery since not being vaccinated seriously hurts its chances for success and his long-term outlook. www.cbsnews.com I've never seen such an incredible display of standing by ones' principles. Bravo to you, sir! Know that as your heart beats its last pump you have remained strong in the face of medical oppression and adversity!
With the covid vaccine being provided by the government free of charge, it got me thinking if we should have a similar process for the flu vaccine. I am not sure what other vaccines the government provides for free. I know in my state the hep B vaccine is provided by the state for newborns, but unsure if any others are. The local health department does provide vaccination, but it is run through your insurance/medicaid - not free per se. I know there are those that fall into "healthcare... Read more
Researchers from U.S. Centers for Disease Control and Prevention (CDC) in Atlant...Read more on AuntMinnie.comRelated Reading: Myocarditis linked to COVID-19 affects small number of athletes Is cardiac MRI necessary for following up young athletes after COVID-19? Cardiac MRI assesses myocarditis after COVID-19 vaccination New MRI method detects heart injuries in COVID-19 patients Some children develop myocarditis after COVID-19 mRNA vaccine
Gilead Sciences, which sold the drug for $3 million less than three years ago, still could come out a winner if the drug is approved by the FDA for patients with the blood cancer myelofibrosis.
Musician wants streaming platform to address "fake information" on vaccines. #neilyoung #spotify #joerogan
TUESDAY, Jan. 25, 2022 -- Pfizer Inc. announced Tuesday that it has launched a trial that will compare its existing COVID-19 vaccine against a new version tailored to beat back the highly contagious omicron variant. " While current research and...
TUESDAY, Jan. 25, 2022 -- European Union residents should be able to move freely between the 27 member nations if they have been vaccinated in the past nine months or have recently recovered from COVID-19 infection, bloc officials said Tuesday. The...
Conclusions: The rate of durvalumab utilization was overall low in both the open and closed claims data sources (31% and 53%, respectively). It remains unknown what percent of eligible patients end up receiving durvalumab, as our analysis was unable to filter out patients who were unfit for durvalumab or if they had progression after chemoradiation. Future efforts are needed to increase maintenance durvalumab utilization and to determine how best to manage patients who are unfit for durvalumab.
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Allergy & Immunology | Biology | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Chemotherapy | Colorectal Cancer | Gastric (Stomach) Cancer | Immunotherapy | Kidney Cancer | Leukemia | Liver | Lung Cancer | Molecular Biology | Prostate Cancer | Radiation Therapy | Urology & Nephrology | Vaccines